image credit- shutterstock
ChemPartner, a leading global Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), has announced its strategic expansion in the US with the upcoming opening of the ChemPartner Boston Centre of Excellence.
Located at 480 Arsenal Way in Watertown, MA, the new R&D site will commence operations on September 10, 2025, providing discovery and preclinical services to biopharma clients in North America and beyond.
ChemPartner's new US site, located in the heart of the Boston biotech corridor, is designed to strengthen collaboration with the region's innovative biotech and pharmaceutical community.
Offering biologics discovery, pharmacology, and DMPK services, the site supports both in vitro and in vivo studies from early discovery through IND-enabling stages. As an extension of ChemPartner's global network, it enhances flexibility for North American partners needing onshore capabilities while improving logistics and enabling faster, more seamless coordination across regions.
The facility spans approximately 12,000 square feet and will open with an experienced scientific team ready to support clients locally and globally. Equipment installation is underway, with initial projects slated to launch this fall.
